COVID vaccine creator BioNTech to buy mRNA drugmaker CureVac for $1.25 billion
MLex Summary: German pharmaceutical company BioNTech, which collaborated with Pfizer to create a globally popular COVID vaccine, intends to purchase mRNA treatment designer CureVac for roughly $1.25 billion, according to a...To view the full article, register now.
Already a subscriber? Click here to view full article